Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Efficacy and safety of switching from the DPP-4 inhibitor of sitagliptin to human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with diabetes type 2: a randomized, open-label trial